Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.
Daniel R. Kuritzkes, MD
Chief, Division of Infectious
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)
European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)
Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)
Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)